Eupraxia Pharmaceuticals (EPRX) Competitors $7.10 +0.16 (+2.31%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.00 -0.09 (-1.34%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. PGEN, AMLX, ATAI, IMTX, and VIRShould you buy Eupraxia Pharmaceuticals stock or one of its competitors? MarketBeat compares Eupraxia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eupraxia Pharmaceuticals include Precigen (PGEN), Amylyx Pharmaceuticals (AMLX), Atai Beckley (ATAI), Immatics (IMTX), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. EPRX vs. PGENEPRX vs. AMLXEPRX vs. ATAIEPRX vs. IMTXEPRX vs. VIRHow does Eupraxia Pharmaceuticals compare to Precigen?Precigen (NASDAQ:PGEN) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Does the media prefer PGEN or EPRX? In the previous week, Eupraxia Pharmaceuticals had 5 more articles in the media than Precigen. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 7 mentions for Precigen. Precigen's average media sentiment score of 0.91 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Which has preferable valuation and earnings, PGEN or EPRX? Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Precigen. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$9.68M156.16-$250.64M-$1.18N/AEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/A Is PGEN or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Precigen's net margin of -646.99%. Precigen's return on equity of 717.50% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Precigen-646.99% 717.50% 58.48% Eupraxia Pharmaceuticals N/A -87.56%-51.20% Do analysts rate PGEN or EPRX? Precigen currently has a consensus price target of $11.00, suggesting a potential upside of 159.43%. Eupraxia Pharmaceuticals has a consensus price target of $18.33, suggesting a potential upside of 158.22%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Which has more risk & volatility, PGEN or EPRX? Precigen has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market. Do insiders and institutionals hold more shares of PGEN or EPRX? 33.5% of Precigen shares are owned by institutional investors. 47.1% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPrecigen and Eupraxia Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.How does Eupraxia Pharmaceuticals compare to Amylyx Pharmaceuticals?Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership. Do institutionals and insiders hold more shares of EPRX or AMLX? 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, EPRX or AMLX? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/AAmylyx Pharmaceuticals$87.37M17.28-$144.74M-$1.50N/A Do analysts prefer EPRX or AMLX? Eupraxia Pharmaceuticals presently has a consensus price target of $18.33, indicating a potential upside of 158.22%. Amylyx Pharmaceuticals has a consensus price target of $23.00, indicating a potential upside of 69.37%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89Amylyx Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77 Which has more risk & volatility, EPRX or AMLX? Eupraxia Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Does the media favor EPRX or AMLX? In the previous week, Eupraxia Pharmaceuticals had 10 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 2 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.12 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Amylyx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EPRX or AMLX more profitable? Amylyx Pharmaceuticals' return on equity of -55.69% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -87.56% -51.20% Amylyx Pharmaceuticals N/A -55.69%-50.73% SummaryEupraxia Pharmaceuticals beats Amylyx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.How does Eupraxia Pharmaceuticals compare to Atai Beckley?Atai Beckley (NASDAQ:ATAI) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Do institutionals & insiders believe in ATAI or EPRX? 28.4% of Atai Beckley shares are held by institutional investors. 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer ATAI or EPRX? Atai Beckley presently has a consensus target price of $16.00, indicating a potential upside of 270.37%. Eupraxia Pharmaceuticals has a consensus target price of $18.33, indicating a potential upside of 158.22%. Given Atai Beckley's stronger consensus rating and higher probable upside, equities analysts clearly believe Atai Beckley is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atai Beckley 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Which has more volatility & risk, ATAI or EPRX? Atai Beckley has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Which has better valuation & earnings, ATAI or EPRX? Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Atai Beckley. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtai Beckley$4.09M388.87-$660.05M-$2.23N/AEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/A Does the media prefer ATAI or EPRX? In the previous week, Eupraxia Pharmaceuticals had 2 more articles in the media than Atai Beckley. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 10 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.99 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that Atai Beckley is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Is ATAI or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Eupraxia Pharmaceuticals' return on equity of -87.56% beat Atai Beckley's return on equity.Company Net Margins Return on Equity Return on Assets Atai Beckley-19,019.44% -89.79% -63.58% Eupraxia Pharmaceuticals N/A -87.56%-51.20% SummaryAtai Beckley beats Eupraxia Pharmaceuticals on 9 of the 15 factors compared between the two stocks.How does Eupraxia Pharmaceuticals compare to Immatics?Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Is EPRX or IMTX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -87.56% -51.20% Immatics -572.35%-47.36%-39.35% Which has preferable earnings and valuation, EPRX or IMTX? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Immatics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/AImmatics$54.60M28.53-$222.26M-$1.99N/A Do institutionals & insiders hold more shares of EPRX or IMTX? 64.4% of Immatics shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, EPRX or IMTX? Eupraxia Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Immatics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market. Do analysts recommend EPRX or IMTX? Eupraxia Pharmaceuticals presently has a consensus target price of $18.33, suggesting a potential upside of 158.22%. Immatics has a consensus target price of $19.00, suggesting a potential upside of 63.51%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89Immatics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor EPRX or IMTX? In the previous week, Eupraxia Pharmaceuticals had 11 more articles in the media than Immatics. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 1 mentions for Immatics. Immatics' average media sentiment score of 0.00 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that Immatics is being referred to more favorably in the news media. Company Overall Sentiment Eupraxia Pharmaceuticals Negative Immatics Neutral SummaryImmatics beats Eupraxia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?Vir Biotechnology (NASDAQ:VIR) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Which has higher earnings and valuation, VIR or EPRX? Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVir Biotechnology$68.56M22.61-$437.99M-$3.13N/AEupraxia PharmaceuticalsN/AN/A-$38.58M-$1.05N/A Does the media prefer VIR or EPRX? In the previous week, Eupraxia Pharmaceuticals had 8 more articles in the media than Vir Biotechnology. MarketBeat recorded 12 mentions for Eupraxia Pharmaceuticals and 4 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.37 beat Eupraxia Pharmaceuticals' score of -0.53 indicating that Vir Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative Is VIR or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vir Biotechnology-638.88% -53.31% -41.76% Eupraxia Pharmaceuticals N/A -87.56%-51.20% Do analysts recommend VIR or EPRX? Vir Biotechnology presently has a consensus price target of $20.25, suggesting a potential upside of 120.35%. Eupraxia Pharmaceuticals has a consensus price target of $18.33, suggesting a potential upside of 158.22%. Given Eupraxia Pharmaceuticals' higher probable upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Vir Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89 Do institutionals and insiders have more ownership in VIR or EPRX? 65.3% of Vir Biotechnology shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, VIR or EPRX? Vir Biotechnology has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. SummaryVir Biotechnology beats Eupraxia Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition ExportMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$419.42M$3.37B$6.40B$12.31BDividend YieldN/A2.28%2.76%5.31%P/E Ratio-6.7618.9321.0025.66Price / SalesN/A325.37556.1383.75Price / CashN/A131.8944.5756.72Price / Book4.037.1110.377.14Net Income-$38.58M$24.45M$3.56B$335.72M7 Day Performance2.60%3.32%5.10%3.03%1 Month Performance-2.07%2.13%3.58%2.88%1 Year Performance83.46%63.43%34.18%35.20% Eupraxia Pharmaceuticals Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.231 of 5 stars$7.10+2.3%$18.33+158.2%+87.6%$419.42MN/AN/A29Analyst ForecastAnalyst RevisionHigh Trading VolumePGENPrecigen3.9812 of 5 stars$4.28+0.2%$11.00+157.0%+205.0%$1.52B$9.68MN/A190News CoverageAnalyst UpgradeAnalyst RevisionAMLXAmylyx Pharmaceuticals2.9882 of 5 stars$13.93+2.4%$23.00+65.1%+153.4%$1.51B$87.37MN/A200Positive NewsATAIAtai Beckley4.0015 of 5 stars$4.33+5.9%$16.00+269.5%+113.9%$1.51B$4.09MN/A80Positive NewsAnalyst RevisionGap UpIMTXImmatics1.9588 of 5 stars$11.06-1.4%$19.00+71.8%+123.5%$1.50B$54.60MN/A260Analyst Forecast Related Companies and Tools Related Companies Precigen Competitors Amylyx Pharmaceuticals Competitors Atai Beckley Competitors Immatics Competitors Vir Biotechnology Competitors Immunocore Competitors MBX Biosciences Competitors Damora Therapeutics, Inc. Common Stock Competitors Urogen Pharma Competitors Compass Pathways Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
